Clorinda Schettino

Naples, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 27 publications

Inavolisib for PIK3CA-mutated advanced endometrial cancer: a multicentric, phase II, MITO END-4 trial.

Inavolisib for PIK3CA-mutated advanced endometrial cancer: a multicentric, phase II, MITO END-4 trial.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: April 27, 2026

The impact of body mass index on survival and surgical outcomes in ovarian cancer: insights from the MITO trials.

The impact of body mass index on survival and surgical outcomes in ovarian cancer: insights from the MITO trials.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: July 29, 2025

Homologous recombination repair status in advanced endometrial cancer: an exploratory biomarker analysis from the randomized, phase II MITOEND 3 trial.

Homologous recombination repair status in advanced endometrial cancer: an exploratory biomarker analysis from the randomized, phase II MITOEND 3 trial.

Journal: ESMO open

Published: July 02, 2025

Comparison of baseline patient characteristics in phase 1 and phase 2/3 clinical trials for anticancer treatments.

Comparison of baseline patient characteristics in phase 1 and phase 2/3 clinical trials for anticancer treatments.

Journal: Journal of translational medicine

Published: February 11, 2025

Association of peripheral monocytic myeloid-derived suppressor cells with molecular subtypes in single-center endometrial cancer patients receiving carboplatin + paclitaxel/avelumab (MITO-END3 trial).

Association of peripheral monocytic myeloid-derived suppressor cells with molecular subtypes in single-center endometrial cancer patients receiving carboplatin + paclitaxel/avelumab (MITO-END3 trial).

Journal: Cancer immunology, immunotherapy : CII

Published: January 16, 2025

Corrigendum to "Under-reporting of subjective symptoms and its prognostic value: a pooled analysis of 12 cancer clinical trials": [ESMO Open 9 (2024) 102941].

Corrigendum to "Under-reporting of subjective symptoms and its prognostic value: a pooled analysis of 12 cancer clinical trials": [ESMO Open 9 (2024) 102941].

Journal: ESMO open

Published: December 01, 2024

Ten-year update of HOBOE phase III trial comparing triptorelin plus either tamoxifen or letrozole or zoledronic acid + letrozole in premenopausal hormone receptor-positive early breast cancer patients.

Ten-year update of HOBOE phase III trial comparing triptorelin plus either tamoxifen or letrozole or zoledronic acid + letrozole in premenopausal hormone receptor-positive early breast cancer patients.

Journal: ESMO open

Published: September 05, 2024

Unlocking the potential of Molecular Tumor Boards: from cutting-edge data interpretation to innovative clinical pathways.

Unlocking the potential of Molecular Tumor Boards: from cutting-edge data interpretation to innovative clinical pathways.

Journal: Critical reviews in oncology/hematology

Published: January 30, 2024

Under-reporting of subjective symptoms and its prognostic value: a pooled analysis of 12 cancer clinical trials.

Under-reporting of subjective symptoms and its prognostic value: a pooled analysis of 12 cancer clinical trials.

Journal: ESMO open

Published: January 03, 2024

MITO END-3: efficacy of avelumab immunotherapy according to molecular profiling in first-line endometrial cancer therapy.

MITO END-3: efficacy of avelumab immunotherapy according to molecular profiling in first-line endometrial cancer therapy.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: August 23, 2023

Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial.

Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial.

Journal: The Lancet. Oncology

Published: November 07, 2022

Biological and clinical impact of membrane EGFR expression in a subgroup of OC patients from the phase IV ovarian cancer MITO-16A/MANGO-OV2A trial.

Biological and clinical impact of membrane EGFR expression in a subgroup of OC patients from the phase IV ovarian cancer MITO-16A/MANGO-OV2A trial.

Journal: Journal of experimental & clinical cancer research : CR

Published: August 26, 2022

Showing 1-12 of 27

Last Updated: 09/26/2026